<DOC>
	<DOCNO>NCT02364804</DOCNO>
	<brief_summary>The purpose study evaluate efficacy anti-emetic drug Aprepitant upon combination chemotherapy nedaplatin docetaxel non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Anti-emetic Drug Upon Combination Chemotherapy Non-small Cell Lung Cancer</brief_title>
	<detailed_description>The purpose study evaluate efficacy anti-emetic drug Aprepitant upon combination chemotherapy nedaplatin docetaxel non-small cell lung cancer ( NSCLC ) . The incidence grade chemotherapy-induced nausea vomit ( CINV ) assess patient receive Aprepitant prevention CINV upon combination chemotherapy nedaplatin docetaxel NSCLC . These data compare survey retrospectively patient receive combination chemotherapy anti-emetic agent except Aprepitant .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>1 . Patients receive combination chemotherapy nedaplatin docetaxel treatment adjuvant therapy nonsmall cell lung cancer . 2 . ECOG performance status 01 . 3 . Aged 2079 year old . 4 . Laboratory value follow 4000/mm3 &lt; WBC &lt; 12000/mm3 , neutrophil count &gt; 2000/mm3 , platelet count &gt; 100000/mm3 , hemoglobin &gt; 9.5g/dL , asparate transaminase &lt; 2.5 X cutoff value , alanine transaminase &lt; 2.5 X cutoff value , total bilirubin &lt; 1.5g/dL , Serum creatinine &lt; cutoff value , PaO2 &gt; 60 Torr . 5 . Able willing give valid write informed consent . 1 . Allergy polysorbert 80 platinumcontaining drug . 2 . Severe complication ( i.e . ischemic heart diseases require treatment , arrhythmia , myocardial infarction within 6 month , liver cirrhosis , uncontrolled diabetes , hemorrhagic tendency ) . 3 . Active uncontrolled infectious disease . 4 . Massive pleural pericardial effusion . 5 . Other malignancy require treatment . 6 . Active interstitial pneumonitis past historyBreastfeeding Pregnancy ( woman child bear potential ) 7 . Peripheral nerve disorder . 8 . Pregnant lactating woman . 9 . Concurrent administration pimozide . 10 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>